

2011 Annual Report / 2010 Statistical Data / Lung Cancer Focus

ONCOLOGY PROGRAM



MESSAGE FROM OUR CHAIRMAN



The Good Samaritan Cancer Program had a great year of growth and achievement, allowing us to keep in the forefront of cancer therapy. This past year, we obtained digital mammography and acquired a cone beam CT for radiation therapy, allowing us to better localize our treatment to the cancer and decrease the radiation to surrounding tissue.

Dr. Lynne Skaryak, a minimally invasive thoracic surgeon and Dr. Joseph DiRocco, a minimally invasive colorectal surgeon have joined our staff. These surgeons will afford us the opportunity to perform cancer surgery in the lung and abdominal cavity with less side effects and allow patients a quicker recovery time.

Dr. Skaryak has initiated a multi-disciplinary lung cancer clinic at Good Samaritan Hospital.

This will improve our coordination of care for lung cancer, our most commonly diagnosed cancer.

Dr. Thomas Reid, a medical oncologist has become the head of the combined Good Samaritan Hospital/Union Memorial Hospital cancer program. The program also allows us to expand our access to state-of-the-art therapy.

In conjunction with Union Memorial Hospital, we initiated holding a quarterly combined Neuro-Oncology Tumor Conference to discuss treatment planning and diagnosis.

Under research, Heather Williams, a research nurse, joined our staff. Subsequently, we have been approved by CALGB to participate in national clinical trials, giving our patients access to cutting-edge clinical research.

Under quality initiatives, our program has, once again, been approved for three years with commendation by the American College of Surgeons. In addition, we are participating with the American Society of Clinical Oncology and Medicare in performing quality care reviews.

In the next year, we plan to add a genetic counseling program, survivorship program and expand the cancer fatigue program. Also planned is increased access to PET/CT and expansion of our MedStar North Oncology Program.

Dans Hahn

LUNG CANCER, ALTHOUGH DECREASING IN INCIDENCE OVER THE past five years, is still the number one cause of cancer deaths in both males and females. In 2011, approximately 220,000 people will be diagnosed as having lung cancer. The causes of lung cancer are multiple [i.e. radon environment, radioactive material, etc.], but smoking remains the leading causative agent and to date, anti-smoking campaigns and legislation have had minimal impact in reducing the incidence rate.

In 2010, 59 new lung cancer cases were diagnosed at Good Samaritan Hospital. Twenty-six were female [44 percent] and 33 were male [56 percent]. Ninety-three percent of our new cases were current [25] or previous [30] smokers. Our patient population was older than the national average, with 15 percent younger than 60 years of age and 85 percent, 60 years and older. Twenty-Five percent had early stage disease [Stages 1 and 2], 29 percent had regional stage disease [Stage 3] and 45 percent had metastatic disease [see graph]. These are essentially identical to Maryland and the National averages. Seven patients had Small Cell Lung Cancer and 52 had Non-Small Cell Lung Cancer.

The purpose of this patient care evaluation was to ensure that our patients are receiving appropriate therapy—surgery or radiation alone for Stage 1 Non Small Cell Lung Cancer; combination therapy for Stage 2 and Stage 3 Non Small Cell Lung Cancer and Small Cell Lung Cancer; and palliative care for Stage 4 cancer. All treated patients with Stage 1 received either surgery or radiation therapy. Sixty-one percent of treated patients with Stage 2 and 3 lung cancer, received combination chemotherapy. This was better than the national average of 22 percent. The 39 percent of patients, who received single modality therapy, either refused combination therapy or were not offered the combination for medical reasons. This resulted in a five year survival rate essentially identical to the national average.

Our goals for the future are to continue to try to decrease our incidence of lung cancer through our smoking cessation program. We also plan to establish a lung cancer screening program and participate in lung cancer clinical trials.

In conclusion, Good Samaritan continues to offer, in a very user-friendly, patient-oriented setting, state-of-the-art therapy with access to advanced technology for lung cancer patients, utilizing combined modality treatment where medically indicated.

focus: LUNG CANCER





The Good Samaritan Hospital is pleased to have introduced the Cancer Fatigue Program as part of its treatment for oncology patients. The program began in early 2011 in an effort to treat the fatigue that is so prevalent among patients with cancer.

Feeling tired is the number one complaint expressed by our patients, and may be caused by the cancer treatments, the tumor itself, poor nutrition, pain, lack of sleep, stress, and lack of exercise. Because fatigue is a multidimensional problem, we believe the treatment should also be multidimensional.

During initial treatment, the patient is introduced to the concept that the healthy habits he learns in this program will not only increase endurance during treatment but will become a part of his life even when treatment is finished. To that end, the patient is scheduled to see a nutritionist, a mental

spollight: CANCER FATIGUE PROGRAM

health professional, physical and occupational therapy, and a pain management specialist. The patients are assessed by these professionals and coordinated treatment plans are developed.

During the course of the cancer journey, fatigue levels are assessed monthly, and appropriate treatment is prescribed. We monitor and treat anemia, electrolyte imbalances, thyroid function and more, prescribing medication, if needed, to improve fatigue. The cancer fatigue team meets periodically to discuss the progress and treatments of its patients. We hope to add many more patients to our program in the coming year.

FOLLOW-UP OF ALL LIVING PATIENTS IS VITAL TO THE CANCER REGISTRY.

This information assists physicians when accessing patients who may return for checkups, aids in early identification of recurrences and helps to determine treatment. In 2010, the average follow-up rate at Good Samaritan was 92 percent from the registry reference date [2005] and 93 percent for the past five-year reference date. During the middle of the year, it was recommended that we update our reference year from 1995 to 2005. This was approved by ACoS in June and the above numbers reflect the new dates and percentage rates.

OLLOW-UP RATES

	2005 Reference Year	5-Year Reference
Total Patients in Registry	2632	2210
Less Benign and Borderline Cases	7	7
Less CA in Situ Cervix	15	8
Less Basal and Squamous Cell Can	cer of Skin 10	7
Less Foreign Residents	0	0
Less Patients Over 100 Years of Ag	e 2	2
Less Non Analytic	400	315
Less Class of Case 0	53	53
Subtotal	2145	1818
Less Deceased Patients	989	796
Adjusted Total [Living Patients]	1156	1022
Less Patients Known Alive	984	894
Total Lost to Follow-up	172	128
Successful Follow-up	92%	93%
Target	80%	90%


COMPARISON of common cancers


In 2010, the cancer registry accessioned 358 new, analytic cases into the database. The five most common malignancies seen at Good Samaritan Hospital during 2010 exhibit some changes since last year's report. While lung cancer still tops the list at 18 percent, the incidence of lung cancer diagnosed at Good Samaritan has decreased by 1 percent from the previous report [20 to 19 percent], but remains our number one diagnosed cancer.


Colon cancer [14 percent] has become our second most diagnosed cancer at Good Samaritan but fourth nationally and in the state. These are followed by breast [11 percent], which has dropped to third at Good Samaritan, but remains ranked as second in the nation and state. Bladder [6 percent], meninges [5 percent] and prostate [4 percent] rank as fourth, fifth and sixth respectively at Good Samaritan. Of note is the fact that cancer of the meninges has taken fifth place at Good Samaritan and prostate has dropped to sixth, while melanoma has taken fifth place nationally and in the state.

PRIMARY SITE

Primary Sites	# of cases	percent
Digestive System	89	25%
Respiratory System	69	19.2%
Breast	39	10.9%
Urinary System	38	10.6%
Brain/CNS	19	5.3%
Male Genital	17	4.7%
Endocrine	14	3.9%
Oral Cavity & Pharynx	13	3.6%
Lymphoma	12	3.3%
Leukemia	12	3.3%
Female Genital	11	3.1%
Skin	10	2.8%
Multiple Myeloma	6	1.7%
Soft Tissue	2	.6%
Eyes & Orbit	1	.3%
Unknown primary	6	1.7%
Total	358	100







COMPREHENSIVE SERVICES



ONCOLOGIC SURGERY

Cryoablation

General, Abdominal, Thoracic, Head and Neck, Neurologic, Urologic and Gynecologic Surgery

Sentinel Lymph Node Biopsy for Breast and Melanoma

MEDICAL ONCOLOGY

Biotherapy

Management of Red Cell, Leukocyte and Platelet Disorders

Outpatient Chemotherapy, Hydration and Infusion Therapy

ONCOLOGY NURSING

Oncology Nursing Society [ONS] Certification

RADIATION ONCOLOGY

3D Conformal therapy Digital Mammography **IMRT**

Physics Support Radiation Safety Officer Simulation, CT Simulator Transportation Assistance Varian 2100 EX Linear **Accelerator**

IMAGING

1.5 Tesla MRI

Nuclear Medicine Studies

PET Scan

Spiral CT Scan

Vascular Interventional Services

HOME CARE & HOSPICE

REHABILITATION

Acute Post-Breast Surgery Rehabilitation Program Inpatient and Outpatient Physical, Speech and Occupational Therapy

Inpatient Comprehensive Rehabilitation Program Lymphedema Management Transitional Care Unit

QUALITY MANAGEMENT

Evaluation Studies

Outcomes Measurement, Analysis and Decision Support

Performance Improvement

Patient Care

Quality of Life Studies

RESEARCH PROGRAM: CLINICAL TRIALS

COMMUNITY OUTREACH & SUPPORT SERVICES

Cancer Screening and Education Program

Costa Memorial Support Services Program

Parish Nurse Program

Pastoral Care

Patient Resource Navigator

THE CANCER COMMITTEE is a standing committee of the Medical Staff that includes membership from diagnostic and therapeutic specialties, as well as allied health professionals and other staff involved with the cancer patient care team. The purpose of the Cancer Committee is to oversee all issues related to cancer care, and to identify, assess, organize, plan and implement cancer-related activities at Good Samaritan. The Cancer Committee meets quarterly, maintains a permanent record of its findings, proceedings and actions, and reports to the Medical Executive Committee [MEC].

Davis Hahn, MD, Chairman - Medical Oncology

Christen Alevizatos, MD - Urology

Jill Anderson, PT - Outpatient Rehabilitation

Dale Buchbinder, MD - Surgery

Terina Chen, MD - Pathology

Kelly Fagan - Case Manager

Paul Fowler, MD - Radiation Oncology

Shelley Garfield - MedStar Health VNA

Francesco Grasso, MD - Colorectal Surgery

Phyllis Gray - Director, Oncology Program

Carole Hayward - Radiation Oncology

Marie Hill, RN - Radiation Oncology

Avraam Karas, MD - Thoracic Surgery

Anne Krackow, PhD - Patient Resource Navigator

Barton Lane, MD - Radiology

Moira Larsen, MD - Pathology

Dennis Lee - Clinical Pharmacist, Oncology

Gail Molinari - American Cancer Society

leanette Nimon, RN, OCN - Oncology Nursing

Charles Padgett, MD - Medical Oncology

Thomas Reid, MD - Chief, Hematology & Med. Oncology

Fr. Jim Reusing - Pastoral Care

Howard Richard, MD - Interventional Radiology

Thomas | Senker - Administration

Lynne Skaryak, MD - Thoracic Surgery

Chris Stromyer, RHIA, CTR - Tumor Registry

Francis Velez, MD - Surgery

Debbie Wagner, RN - Nursing Education

Ken Walsch - Quality Management

leremy Weiner, MD - Surgery

Thomas Wilson, MD - Palliative Medicine

Jennifer Wilkerson - Strategic Planning

Heather Williams, RN - Research Coordinator

Proud to be recognized by the American College of Surgeons.

At Good Samaritan, our providers are focused on offering the best cancer care closer to home. In fact, our oncology program has been recognized by the Commission on Cancer of the American College of Surgeons. Only one in four hospitals that treat cancer receives this special approval. It is a recognition of the quality of our comprehensive, multidisciplinary patient care.



Good Samaritan Hospital 5601 Loch Raven Boulevard Baltimore, MD 21239

443.444.8000

goodsam-md.org